This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.

Inclusion Criteria:

• Advanced malignant solid tumors for which no curative therapy exists that has recurred or pgrogressed following standard therapy
• Eighteen years of age or above
• Able to understand and sign an informed consent (or have a legal representative who is able to do so)
• Measurable disease according to RECIST v1.1
• ECOG Performance Score of 0 or 1
• Adequate bone marrow, hepatic, renal and cardiac function
• Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-141

Exclusion Criteria:

• Active infection or fever > 38.5°C during screening visits or on the first scheduled day of dosing
• Symptomatic CNS disease
• Received other recent antitumor therapy
• Pregnant or breast feeding